Press Release

^{18}F-Flutrahexin is here!

Copenhagen, Denmark & Radeberg,Germany, October 8th, 2024

TetraKit Technologies and TRIMT are proud to announce the successful completion of the first steps of the preclinical development of **^{18}F-Flutrahexin**, a fluorine-18 labeled analog of ^{68}Ga-Trivehexin, the currently best-in-class clinical-stage αvβ6-integrin PET tracer [1]. The successful synthesis and pilot *in-vivo* investigation of **^{18}F-Flutrahexin** suggest a great potential for advanced PET diagnostics of cancers with high expression of the tumor cell marker αvβ6-integrin, particularly pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal and ovarian cancers, and parathyroid adenoma.

TetraKit Technologies, known for its innovative TetraKit Platform for multipurpose theranostic radiolabeling of biomolecules, has collaborated with TRIMT, a world-leading specialist for αvβ6-integrin targeting molecules intended to diagnose and cure cancer and other life-threatening diseases. Together, they have pioneered the development of **^{18}F-Flutrahexin** for diagnostic purposes. Of note, this new compound also opens the door to therapeutic applications using beta and alpha-emitting radionuclides such as iodine-131 (^{131}I) or astatine-211 (^{211}At), as well as iodine-123 for SPECT imaging, via the TetraKit Platform.

TetraKit Technologies and TRIMT are actively seeking partnerships to advance the clinical application and development of ^{18}F-Flutrahexin. This also presents an opportunity to further extend the TetraKit radiolabeling platform to novel targets in nuclear and precision medicine. Collaborating with us offers partners a unique chance to lead innovation in this field.

[1] Kimura RH, Iagaru A, Guo HH. Mini review of first-in-human integrin αvβ6 PET tracers. *Front. Nucl. Med.* **2023**;3:1271208. https://doi.org/10.3389/fnume.2023.1271208

About TETRAKIT

TetraKit Technologies is the developer of the TetraKit Platform, a novel technology designed for practical and kit-like theranostic radiolabeling of any biomolecule. The company specializes in the use of iodine-123, iodine-131, astatine-211 and fluorine-18, focusing on radioligand therapy and PET imaging. Founded in 2021 in Copenhagen, Denmark, TetraKit Technologies is at the forefront of innovation in the radiopharmaceutical industry.

About TRIMT

TRIMT GmbH is a clinical-stage company developing novel radiopharmaceuticals for tandem diagnosis and treatment ("Theranostics") of life-threatening diseases. The company was founded in early 2021 in Radeberg near Dresden. TRIMT holds worldwide licenses and possesses a genuine IP portfolio, which covers various classes of structural motifs for biological targeting in the context of cancer and beyond.

Contacts

Dr. Jakub Simecek (CEO)
TRIMT GmbH
Carl-Eschebach-Str. 7
01454 Radeberg, Germany
E: info@trimt.de
www.trimt.de

Dr. Andreas I. Jensen (CEO)
TetraKit Technologies ApS
Ole Maaløes Vej 3
2200 Copenhagen, Denmark
E: andreas.jensen@tetrakit.com
www.tetrakit.com